Wilms tumor protein 1-derived peptide–MHC complex (WT1-pMHC)

Wilms tumor protein 1 (WT1) is a zinc-finger transcription factor that plays a crucial role in cell growth and differentiation, particularly during urogenital development (Source: UniProt P19544). While its expression is highly restricted in healthy adult tissues, it is significantly overexpressed in various hematological malignancies, such as acute myeloid leukemia, and several solid tumors, including mesothelioma and ovarian cancer (Source: National Cancer Institute). The WT1-derived peptide–MHC complex represents the processed form of the WT1 protein presented on the cell surface, which serves as a specific target for the immune system to identify and eliminate malignant cells (Source: PubMed, PMID: 17460054). Therapeutic strategies targeting this complex include peptide vaccines like Galinpepimut-S, T-cell receptor (TCR) engineered T-cells, and TCR-mimic bispecific antibodies (Source: Journal of Hematology & Oncology, 2021). These therapies aim to exploit the high tumor-specificity of the WT1-pMHC complex to induce a potent and selective anti-tumor immune response while minimizing damage to normal tissues. Because WT1 is an intracellular protein, the formation of the peptide-MHC complex is essential for its recognition by T-cell-based immunotherapies.

Other names

WT1-HLA complexWilms tumor 1 antigen-MHC complexWT1 peptide-HLA-A*02:01WT1-pMHC

Therapeutic agents target the WT1-pMHC complex to induce T-cell mediated cytotoxicity against tumor cells by recognizing specific WT1-derived peptides presented by MHC molecules.